Catalyst Pharmaceuticals Inc (STU:CN2)
€ 20.71 0.15 (0.73%) Market Cap: 2.46 Bil Enterprise Value: 2.04 Bil PE Ratio: 18.19 PB Ratio: 3.87 GF Score: 88/100

Q1 2023 Catalyst Pharmaceuticals Inc Earnings Call Transcript

May 11, 2023 / 12:30PM GMT
Release Date Price: €15 (-4.79%)
Operator

Greetings, and welcome to the Catalyst Pharmaceuticals First Quarter 2023 Financial Results Conference Call. (Operator Instructions) As a reminder this conference is being recorded.

It is now my pleasure to introduce your host, Ali Grande, Chief Financial Officer. Thank you, Ali. You may begin.

Alicia Grande
Catalyst Pharmaceuticals, Inc. - CAO, VP, Treasurer & CFO

Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's first quarter 2023 financial results and corporate highlights. Leading the call today is Patrick McEnany, Chairman and Chief Executive Officer. We're also joined by Dr. Steven Miller, our Chief Operating Officer and Chief Scientific Officer; and Jeffrey Del Carmen, our Chief Commercial Officer. Further, for the Q&A session, we'll have Dr. Gary Ingenito, our Chief Medical and Regulatory Officer.

Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we will make statements about expected future results which may be forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot